/**/ RNS Number : 2244B IQ-AI Limited 30 September 2022 IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB: IQAIF: LSE: IQAI), summarises the Company’s achievements in 2022 to date, which includes: · Company focuses on deployment of IB Clinic™ · IB NIMBLE™ connects experts to help treat
/**/ RNS Number : 5398A IQ-AI Limited 26 September 2022 26 September 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Issue of Warrants to Employees IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients
/**/ RNS Number : 1650W IQ-AI Limited 16 August 2022 16 August 2022 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2022 Chief Executive’s Statement I am pleased to announce IQ-AI Limited’s unaudited financial results for the six months ended 30 June 2022. For further information,
/**/ RNS Number : 8120U IQ-AI Limited 03 August 2022 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
/**/ RNS Number : 9294R IQ-AI Limited 11 July 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Announces Channel Partnership IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution
/**/ RNS Number : 3069N IQ-AI Limited 31 May 2022 31 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022: Imaging Biometrics, LLC (IB),
/**/ RNS Number : 1476K IQ-AI Limited 03 May 2022 3 May 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) IB Neuro’s Quantitative Mapping Method Assesses Metastatic Tumors Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue Milwaukee – 3 May 2022: Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:
/**/ RNS Number : 7683J IQ-AI Limited 28 April 2022 28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”) Publication of Annual Report The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.